These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32335702)

  • 1. In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy.
    Marcelis L; Antoranz A; Delsupehe AM; Biesemans P; Ferreiro JF; Debackere K; Vandenberghe P; Verhoef G; Gheysens O; Cattoretti G; Bosisio FM; Sagaert X; Dierickx D; Tousseyn T
    Cancer Immunol Immunother; 2020 Sep; 69(9):1751-1766. PubMed ID: 32335702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
    Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
    Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population.
    Parkhi M; Chatterjee D; Bal A; Vias P; Yadav BS; Prakash G; Gupta SK; Radotra BD
    APMIS; 2022 Feb; 130(2):82-94. PubMed ID: 34862664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmablastic Lymphomas: Characterization of Tumor Microenvironment Using CD163 and PD-1 Immunohistochemistry.
    Ahn JS; Al-Habib A; Vos JA; Sohani AR; Barboza-Quintana O; Flores JP; Wen S; Rosado FG
    Ann Clin Lab Sci; 2020 Mar; 50(2):213-218. PubMed ID: 32366559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.
    Gandhi MK; Hoang T; Law SC; Brosda S; O'Rourke K; Tobin JWD; Vari F; Murigneux V; Fink L; Gunawardana J; Gould C; Oey H; Bednarska K; Delecluse S; Trappe RU; Merida de Long L; Sabdia MB; Bhagat G; Hapgood G; Blyth E; Clancy L; Wight J; Hawkes E; Rimsza LM; Maguire A; Bojarczuk K; Chapuy B; Keane C
    Blood; 2021 Mar; 137(11):1468-1477. PubMed ID: 33202420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy.
    Yanik EL; Kaunitz GJ; Cottrell TR; Succaria F; McMiller TL; Ascierto ML; Esandrio J; Xu H; Ogurtsova A; Cornish T; Lipson EJ; Topalian SL; Engels EA; Taube JM
    JAMA Oncol; 2017 Jul; 3(7):974-978. PubMed ID: 28334399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL).
    Berghoff AS; Ricken G; Widhalm G; Rajky O; Hainfellner JA; Birner P; Raderer M; Preusser M
    Clin Neuropathol; 2014; 33(1):42-9. PubMed ID: 24359606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the tumor microenvironment in primary central nervous system lymphoma: Implications for prognosis.
    Shi H; Sun X; Wu Y; Cui Q; Sun S; Ji N; Liu Y
    J Clin Neurosci; 2024 Jun; 124():36-46. PubMed ID: 38642434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic correlates of
    Sethi TK; Kovach AE; Grover NS; Huang LC; Lee LA; Rubinstein SM; Wang Y; Morgan DS; Greer JP; Park SI; Ann Thompson-Arildsen M; Yenamandra A; Vnencak-Jones CL; Reddy NM
    Leuk Lymphoma; 2019 Dec; 60(12):2880-2889. PubMed ID: 31184237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study.
    Hayano A; Komohara Y; Takashima Y; Takeya H; Homma J; Fukai J; Iwadate Y; Kajiwara K; Ishizawa S; Hondoh H; Yamanaka R
    Anticancer Res; 2017 Oct; 37(10):5655-5666. PubMed ID: 28982883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
    Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
    Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the Immune Microenvironment in Hepatocellular Carcinoma.
    Yarchoan M; Xing D; Luan L; Xu H; Sharma RB; Popovic A; Pawlik TM; Kim AK; Zhu Q; Jaffee EM; Taube JM; Anders RA
    Clin Cancer Res; 2017 Dec; 23(23):7333-7339. PubMed ID: 28928158
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting the polarization of tumor-associated macrophages and modulating mir-155 expression might be a new approach to treat diffuse large B-cell lymphoma of the elderly.
    Poles WA; Nishi EE; de Oliveira MB; EugĂȘnio AIP; de Andrade TA; Campos AHFM; de Campos RR; Vassallo J; Alves AC; Scapulatempo Neto C; Paes RAP; Landman G; Zerbini MCN; Colleoni GWB
    Cancer Immunol Immunother; 2019 Feb; 68(2):269-282. PubMed ID: 30430204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling.
    Alame M; Cornillot E; Cacheux V; Rigau V; Costes-Martineau V; Lacheretz-Szablewski V; Colinge J
    Theranostics; 2021; 11(8):3565-3579. PubMed ID: 33664848
    [No Abstract]   [Full Text] [Related]  

  • 18. Combined tumor-associated macrophages biomarker predicting extremely poor outcome of patients with primary central nervous system lymphoma.
    Sun X; Wang C; Chen C; Huang J; Wu X; Wang Y; He X; Cao J; Jiang W; Sun P; Li Z
    Hematol Oncol; 2021 Dec; 39(5):625-638. PubMed ID: 34543472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart.
    Chang C; Lin CH; Cheng AL; Medeiros LJ; Chang KC
    Histopathology; 2015 Nov; 67(5):625-35. PubMed ID: 25829022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD8
    Dumont C; Jacquier A; Verine J; Noel F; Goujon A; Wu CL; Hung TM; Desgrandchamps F; Culine S; Carosella ED; Rouas-Freiss N; LeMaoult J
    Cancer Immunol Res; 2019 Oct; 7(10):1619-1632. PubMed ID: 31451484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.